The Department of Health and Human Services today announced a $354 million agreement with a private partnership to make more active pharmaceutical ingredients and generic drugs in the United States to treat patients hospitalized with COVID-19 and prevent shortages of essential medicines.

Under the four-year agreement, Phlow Corporation will partner with Civica Rx, the nonprofit generic drug company created by hospital systems and others; AMPAC Fine Chemicals; the Medicines for All Institute at Virginia Commonwealth University’s College of Engineering and others to rapidly make the active pharmaceutical ingredients and medicines using advanced manufacturing processes.

The contract can be extended up to 10 years to maintain the system and supplies.

Related News Articles

Headline
The National Institute for Occupational Safety and Health this week revoked eight N95 filtering facepiece respirator approvals and four powered air-…
Headline
The Centers for Medicare and Medicaid Services released a FAQ regarding Consolidated Appropriations Act changes for states redetermining Medicaid enrollee…
Headline
Telehealth Access for America, an AHA-supported campaign to protect patient access to critical telehealth services, urged Congress to make permanent certain…
Headline
The Department of Health and Human Services May 11 amended its Public Readiness and Emergency Preparedness Act declaration for COVID-19 to extend…
Headline
The Department of Health and Human Services yesterday released a fact sheet reviewing how the May 11 end of the COVID-19 public health emergency will…
Headline
The Centers for Disease Control and Prevention this week recommended health care facilities use a risk-based assessment, stakeholder input and local metrics to…